The use of coagulation factor concentrates for perioperative bleeding management - a global perspective.

Abstract

KEY IDEAS The use of purified, pathogen‐reduced coagulation factor concentrates instead of a ratio‐driven transfusion protocol using plasma, platelets, or cryoprecipitate may offer a faster, safer, and more specific approach to significantly increase the concentration of coagulation factors in bleeding patients. Available products, on‐label indications, price, and approach to laboratory monitoring differ considerably worldwide. Although evidence regarding optimal thresholds and dose of coagulation factor concentrates to treat massive perioperative bleeding is still limited, recently multiple high‐quality published trials with promising results have been published globally.